We had the privilege to participate in the 13th Conference of the European Hidradenitis Suppurativa Foundation e.V. and presented a poster on exploring how Secukinumab ameliorates the inflammatory phenotype of HS  a diseased human skin organ culture model.

“Unravelling Insights into the Mechanism of Action of Secukinumab in the Inflammatory Phenotype of Hidradenitis Suppurativa: Lessons from Diseased Skin Organ Culture” – Edelkamp J, Pal A, Viola-Söhnlein J, Fehrholz M, Nicodeme E, Bechara F, Schneider-Burrus S, Julia V, Pappelbaum K, Bertolini M

In this study a skin organ culture model using lesional skin of Hidradentitis Suppurativa patients was applied. We could show that the inhibition of IL-17A by Secukinumab modulates pathways associated with IL-1 and TNFα signaling. Consistent with previous findings, IL-17RA/IL-17RC receptor activation induces IL-1 and TNFα signaling, and the expression of pro-inflammatory mediators is modulated by IL-17A interaction with both pathways.
If you want to explore how our lesional HS ex vivo model is an excellent tool for efficacy testing and mechanism of action studies of potential therapeutic candidates for HS treatment, DOWNLOAD the poster here.